• Species Reactivity

  Human

• Specificity

  Detects human BRCA1 C-Terminus in direct ELISAs.

• Source

  Polyclonal Sheep IgG

• Purification

  Antigen Affinity-purified

• Immunogen

  E. coli-derived recombinant human BRCA1 C-Terminus    
  Arg1634-Tyr1863    
  Accession # P38398

• Formulation

  Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.

• Label

  Unconjugated

Applications

• Recommended    
  Concentration

  Sample

• Immunohistochemistry

  5-15 µg/mL

  See below

• 
  

Please Note: Optimal dilutions should be determined by each laboratory for each application.  are available in the Technical Information section on our website.

Data Examples

Preparation and Storage

• Reconstitution

  Sterile PBS to a final concentration of 0.2 mg/mL.

• Shipping

  The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

• Stability & Storage

  Use a manual defrost freezer and avoid repeated freeze-thaw cycles.    

• 12 months from date of receipt, -20 to -70 °C as supplied.

• 1 month, 2 to 8 °C under sterile conditions after reconstitution.

• 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: BRCA1

The BRCA1 (BReast CAncer gene 1) tumor suppressor protein has many reported functions. In addition to mediating signal transduction in DNA damage and repair responses, BRCA1 regulates transcriptional activity and assists in the preservation of chromosomal stability. BRCA1 is one of the first proteins recruited to sites of DNA double-strand breaks, and serves as part of a scaffold for assembling other DNA damage response or repair factors.

• Long Name:

  Breast Cancer 1

• Entrez Gene IDs:

  672 (Human); 12189 (Mouse); 497672 (Rat)

• Alternate Names:

  BRCA1; BRCAI; breast and ovarian cancer susceptibility protein 1; breast and ovarian cancer sususceptibility protein; breast cancer 1, early onset; breast cancer type 1 susceptibility protein; EC 6.3.2; EC 6.3.2.-; IRIS; PNCA4; PSCP; subunit 1